ReviewFrontiers in immunology2022
Immunometabolism in the pathogenesis of vitiligo.
Review in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 34 citations in OpenAlex.
- Markers of Systemic Metabolic Dysfunction in Vitiligo and Their Potential Role in Disease Pathogenesis: A Narrative Review.Health science reports · 2026Article
- [Association of vitiligo with endocrine autoimmune diseases: literature review].Problemy endokrinologii · 2026Review
- The CREM-IL-15 axis: decoding the persistence-exhaustion paradox in NK cell immunotherapy.Cancer immunology, immunotherapy : CII · 2026Review
- Vitiligo-Current Treatment Options and Future Perspectives.International journal of molecular sciences · 2026Review
- Lactate Enhances CD8International journal of molecular sciences · 2026Article
- Ferroptosis as a Pathogenic Mechanism and Therapeutic Target in Autoimmune and Inflammatory Skin Diseases.Clinical reviews in allergy & immunology · 2026Review
- Immunometabolism: A Novel Therapeutic Target and Its Pharmacological Modulation for Intervertebral Disc Degeneration.International journal of molecular sciences · 2026Review
- Minimally invasive 1 mm skin biopsies capture site-specific transcriptomic heterogeneity in vitiligo.Frontiers in immunology · 2026Article
- Evaluation of Oxidative Stress in Red Blood Cells From Vitiligo Patients and Its Correlation With Disease Severity and Activity: A Cohort Case-Control Study.Health science reports · 2026Article
- Mitochondrial dynamics in skin health and disease: energy, aging, and therapeutic perspectives.Burns & trauma · 2026Review
- Spatial multi-omics profiling uncovers metabolic heterogeneity in Sjögren's syndrome and identifies PS(36:1) as a potential therapeutic target.Journal of translational medicine · 2025Article
- Natural protection against oxidative stress in human skin melanocytes.Communications biology · 2025Review
- Cullin-3 and Regulatory Biomolecules Profiling in Vitiligo: Integrated Docking, Clinical, and In Silico Insights.Biomolecules · 2025Article
- Metabolic syndrome and dermatological diseases: association and treatment.Nutrition & metabolism · 2025Review
- Beyond skin deep: exploring the complex molecular mechanisms and holistic management strategies of vitiligo.Archives of dermatological research · 2025Review
- Metabolic anomalies in vitiligo: a new frontier for drug repurposing strategies.Frontiers in pharmacology · 2025Article
- Innate immune activation in vitiligo: mechanisms and pathophysiological implications.Frontiers in immunology · 2025Review
- Identifying potential biomarkers and molecular mechanisms related to arachidonic acid metabolism in vitiligo.Frontiers in molecular biosciences · 2025Article
- Markers of Metabolic Abnormalities in Vitiligo Patients.International journal of molecular sciences · 2024Article
- The role of immune metabolism in skin cancers: implications for pathogenesis and therapy.Translational cancer research · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vitiligo is a common depigmenting skin disorder characterized by the selective loss of melanocytes. Autoimmunity, genetic, environmental, and biochemical etiology have been proposed in vitiligo pathogenesis. However, the exact molecular mechanisms of vitiligo development and progression are unclear, particularly for immunometabolism. Sporadic studies have suggested mitochondrial dysfunction, enhanced oxidative stress, and specific defects in other metabolic pathways can promote dysregulation of innate and adaptive immune responses in vitiligo. These abnormalities appear to be driven by genetic and epigenetic factors modulated by stochastic events. In addition, glucose and lipid abnormalities in metabolism have been associated with vitiligo. Specific skin cell populations are also involved in the critical role of dysregulation of metabolic pathways, including melanocytes, keratinocytes, and tissue-resident memory T cells in vitiligo pathogenesis. Novel therapeutic treatments are also raised based on the abnormalities of immunometabolism. This review summarizes the current knowledge on immunometabolism reprogramming in the pathogenesis of vitiligo and novel treatment options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.